» Articles » PMID: 1656853

Pharmacokinetics and Tissue Penetration of Tazobactam Administered Alone and with Piperacillin

Overview
Specialty Pharmacology
Date 1991 Jun 1
PMID 1656853
Citations 30
Authors
Affiliations
Soon will be listed here.
Abstract

The pharmacokinetics of tazobactam (500 mg) administered intravenously alone were compared with the pharmacokinetics of tazobactam coadministered with piperacillin (4 g), and the penetration into an inflammatory exudate in six healthy males was studied. Piperacillin influenced the pharmacokinetics of tazobactam. The mean levels of tazobactam in plasma at 4 h were 0.6 microgram/ml when it was given alone and 1.2 micrograms/ml when it was given with piperacillin (P = 0.0003). The mean total clearances of tazobactam were 203.5 and 134.2 ml/min (P = 0.035) when it was given alone and with piperacillin, respectively There were no significant differences in the elimination half lives, areas under the concentration-time curve from 0 h to infinity, or volumes of distribution. Inflammatory exudate penetration was rapid, and the mean maximum levels of tazobactam attained were 6.4 and 11.3 micrograms/ml when it was given alone or with piperacillin, respectively (P less than 0.06). The mean percent penetration of tazobactam and the area under the concentration-time curve from 0 h to infinity in inflammatory exudate were greater when tazobactam was given with piperacillin. The mean 24-h urinary recoveries of tazobactam were 63.7% +/- 7.9% when it was given alone and 56.8% +/- 2.7% when it was given with piperacillin. The explanation for the differences in the pharmacokinetics of tazobactam when it was administered alone compared with those when it was given with piperacillin was unclear.

Citing Articles

A Pooled Pharmacokinetic Analysis for Piperacillin/Tazobactam Across Different Patient Populations: From Premature Infants to the Elderly.

Kong D, Roberts J, Lipman J, Taccone F, Cohen-Wolkowiez M, Sime F Clin Pharmacokinet. 2024; 64(1):107-126.

PMID: 39722108 PMC: 11762590. DOI: 10.1007/s40262-024-01460-6.


Real-Life Experience of Continuously Infused Ceftolozane/Tazobactam in Patients with Bronchiectasis and Multidrug-Resistant Infection in the Outpatient Setting.

Venuti F, Gaviraghi A, De Nicolo A, Stroffolini G, Longo B, Di Vincenzo A Antibiotics (Basel). 2023; 12(7).

PMID: 37508309 PMC: 10376517. DOI: 10.3390/antibiotics12071214.


β-Lactam potentiators to re-sensitize resistant pathogens: Discovery, development, clinical use and the way forward.

Narendrakumar L, Chakraborty M, Kumari S, Paul D, Das B Front Microbiol. 2023; 13:1092556.

PMID: 36970185 PMC: 10036598. DOI: 10.3389/fmicb.2022.1092556.


Estimation of cefepime, piperacillin, and tazobactam clearance with iohexol-based glomerular filtration rate in paediatric patients.

Soeorg H, Noortoots A, Karu M, Saks K, Lass J, Lutsar I Eur J Clin Pharmacol. 2022; 78(6):989-1001.

PMID: 35275224 DOI: 10.1007/s00228-022-03307-0.


Tolerability, Safety, Pharmacokinetics and Drug Interaction of Cefotaxime Sodium-Tazobactam Sodium Injection (6:1) Following Single and Multiple Intravenous Doses in Chinese Healthy Subjects.

Chen N, Sun L, Hu W, Wang Y, Xie L, Cheng J Front Pharmacol. 2020; 11:1033.

PMID: 32733255 PMC: 7360824. DOI: 10.3389/fphar.2020.01033.


References
1.
Kuck N, Jacobus N, Petersen P, Weiss W, Testa R . Comparative in vitro and in vivo activities of piperacillin combined with the beta-lactamase inhibitors tazobactam, clavulanic acid, and sulbactam. Antimicrob Agents Chemother. 1989; 33(11):1964-9. PMC: 172796. DOI: 10.1128/AAC.33.11.1964. View

2.
Jones R, Barry A . Studies to optimize the in vitro testing of piperacillin combined with tazobactam (YTR 830). Diagn Microbiol Infect Dis. 1989; 12(6):495-510. DOI: 10.1016/0732-8893(89)90084-9. View

3.
Diver J, Thornber D, Wise R . Protection of piperacillin and ticarcillin from beta-lactamase hydrolysis by tazobactam (YTR-830) and clavulanic acid. J Antimicrob Chemother. 1989; 24(1):89-92. DOI: 10.1093/jac/24.1.89. View

4.
Verbist L . In vitro activity of piperacillin, a new semisynthetic penicillin with an unusually broad spectrum of activity. Antimicrob Agents Chemother. 1978; 13(3):349-57. PMC: 352245. DOI: 10.1128/AAC.13.3.349. View

5.
De Schepper P, Tjandramaga T, MULLIE A, Verbesselt R, Van Hecken A, Verberckmoes R . Comparative pharmacokinetics of piperacillin in normals and in patients with renal failure. J Antimicrob Chemother. 1982; 9 Suppl B:49-57. DOI: 10.1093/jac/9.suppl_b.49. View